In this video, Motley Fool health care analyst Brenton Flynn takes a look at Celgene (NASDAQ:CELG) and its cancer drug Abraxane. The company's shares received a boost on Monday after releasing phase 3 data showing that the drug had a statistically significant impact on survival rates for advanced pancreatic cancer. Flynn takes us through the likelihood of Abraxane getting approval from the Food and Drug Administration, the growth potential in the market for this drug if it is approved, and what that could mean for this company's future.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Celgene Hits the Mark With Abraxane
By Brenton Flynn and Max Macaluso
–
Nov 13, 2012 at 7:00AM
NASDAQ: CELG
Celgene
Abraxane looks poised to receive another indication.
Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.